WEBULL
WebtradeDownload

Is United Therapeutics (UTHR) Undervalued After Its Phase 3 Ralinepag Results?

Simply Wall St · 2d ago

United Therapeutics (UTHR) stock is in focus after the company reported statistically significant phase 3 ADVANCE OUTCOMES results for its investigational PAH therapy ralinepag, with full data recently published in The Lancet.

See our latest analysis for United Therapeutics.

The latest ralinepag data and board appointment of Dr. Victor Dzau come as United Therapeutics trades at US$524.70, with the share price return up 5.63% year to date but the 90-day share price return down 8.16%. Over a longer horizon, the stock has delivered an 86.10% total shareholder return over 1 year and a 154.60% total shareholder return over 5 years, which indicates that momentum has been strong even as recent share price returns have cooled.

If you like the setup around United Therapeutics, it can also be useful to see which other healthcare companies are pushing into AI driven treatments and diagnostics through our 41 healthcare AI stocks

After such strong multi year returns and a recent pullback, the key issue around United Therapeutics is whether the latest ralinepag progress still leaves meaningful upside ahead or if most of the easy gains are already behind the stock.

Most Popular Narrative: 21.1% Undervalued

At a last close of $524.70, the most widely followed narrative for United Therapeutics points to a fair value of $665.23, implying meaningful upside potential based on its underlying assumptions.

The company's innovation wave pipeline, including studies in progressive fibrosis, next-generation delivery platforms (oral, implantable), and organ manufacturing (xenotransplant/3D printing), positions United Therapeutics to benefit from the expanding focus on personalized and regenerative medicine, which can create new revenue streams and margin expansion opportunities as these long-horizon technologies approach clinical milestones and eventual commercialization.

Read the complete narrative.

Curious what justifies that higher fair value for United Therapeutics. The narrative leans on steady revenue expansion, firm margins, and a future earnings multiple that assumes the pipeline delivers more than the current portfolio suggests.

Result: Fair Value of $665.23 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, the United Therapeutics story could change quickly if key trials such as TETON or ADVANCE OUTCOMES disappoint, or if pricing pressure affects the PAH franchise.

Find out about the key risks to this United Therapeutics narrative.

Next Steps

Given the mixed sentiment around United Therapeutics right now, it makes sense to check the underlying data yourself and decide how compelling the rewards really look. To see which positives our work has highlighted and why some investors are optimistic, review the 4 key rewards

Looking for more investment ideas beyond United Therapeutics?

If you want to keep building on your work with United Therapeutics, use the Simply Wall Street Screener to uncover other stocks that could suit your approach.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.